Nilesh Gupta

Lupin CFO Ramesh Swaminathan, also expects lower margin erosion for Spiriva in the US market due to lack of competition from another generic player.

Expect higher demand for inverter ACs & 5-star power-rated ACs: Vijay Sales

In an interview to CNBC-TV18, Nilesh Gupta, Managing Partner of Vijay Sales spoke about the sales outlook and inventory picture.

Drug cos focus on automation & work culture to meet compliance

Faced with increasing regulatory scrutiny -- Indian drug makers working more closely then ever before on Friday said they have been investing on automation, simplifying and standardizing systems and working on building culture of compliance within their organizations -- as they don‘t want to be seen as outliers in terms of regulatory compliance.

Aspire to hit $5 bn in sales soon; focus on specialty biz: Lupin

The Lupin Pharmaceuticals duo MD Nilesh Gupta and CEO Vinita Gupta say current business conditions only permit revenue visibility of USD 3.5 billion, although their aspiration is to hit USD 5 billion soon. They are among the 50 contenders vying for the World Entrepreneur Award currently being hosted by E&Y at Monte Carlo.

Lupin off 8% on weak sales forecast; analysts fret over Goa unit

Majority of brokerages retained their ratings on the stock but half of them slashed target price, citing caution over earnings due to likely higher R&D expenses and cut in FY18 sales guidance by the company.

EY Passion to Win: Here's the success story of the Lupin duo

EY Entrepreneur of the Year 2015 recognised and rewarded India's most exceptional entrepreneur \s and business leaders who have brought about a change through their exemplary work, sheer grit and determination. Celebrating the success stories of these winners is the Passion to Win series showcasing India's best innovators and game changers.

Lupin confident of growth in US going ahead

"I now the first half of this year has been challenging for us. Q3, you have already started seeing recovery. Q4, you will more so and into the next year, but when I think about the business from the next couple of years' perspective, we are set for growth in the US," Vinita Gupta of Lupin says.

No material launch, price erosion impacted earnings: Lupin

Pharma major Lupin reported a very disappointing set of fourth quarter numbers Wednesday with consolidated net profit falling 1.1 percent to Rs 547 crore in January-March quarter from Rs 553 crore in the corresponding quarter last fiscal.

Always believe growth will come from acquisitions: Lupin

Lupin MD Nilesh Gupta explains why revenues are in line with expectations.

Lupin Q3 net profit rises 26% to Rs 601 crore

The company had posted a net profit of Rs 476.13 crore in the same period of previous fiscal. Net sales of the company rose to Rs 3,144.91 crore for quarter under review as compared to Rs 2,982.97 crore in the same period of previous fiscal.

Competition, seasonality led to weak Q2 results: Lupin

The company's consolidated revenue grew by 18.9 percent to Rs 3,173 crore in the quarter ended September 2014 compared to Rs 2,668 crore in corresponding quarter of last fiscal.

Lupin Q3 net at record high, co buys Netherlands' Nanomi

Net profit increased to a record level of Rs 476.1 crore as against Rs 335.2 crore in same quarter last year while revenue grew 20.8 percent year-on-year to Rs 3,022 crore in the quarter gone by.

Why these 8 pharma CEOs will be on investors radar in '14

GV Prasad Reddy and Satish Reddy of Dr Reddy's Labs have a big task at hand - large business restructuring process, reorientation of operations and increasing focus on global markets.

Lupin: In capable young hands

The Lupin founder‘s offspring are building a global generics powerhouse while sitting 8,000 miles apart.

Lupin back on track, may clock 18-20% growth going ahead

Lupin's Q2 numbers were in line with street estimates, with margins slightly higher. MD Nilesh Gupta believes the company is back on its growth trajectory and will post better numbers going forward.

Lupin to rely on Antara sales to rebuild brand: MD

After receiving the USFDA nod for its supplemental new drug application for Antara capsules on Tuesday, Lupin will now focus on building back its brand by gaining its lost market share.

Lupin & Medicis enter into joint development agreement

Lupin Limited announced that it has entered into a research and development agreement with Medicis Pharmaceutical Corporation (“Medicis”) to apply proprietary Lupin formulation technologies to multiple therapeutic compounds.